1594940-99-4

Basic information

• Product Name: (7S,8R,9S,13S,14S,17S)-7-(4-(benzyloxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
• Synonyms: (7S,8R,9S,13S,14S,17S)-7-(4-(benzyloxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
• CAS NO: 1594940-99-4
• Molecular Weight: 536.709
• Mol File: 1594940-99-4.mol

Chemical Properties

• CAS DataBase Reference: (7S,8R,9S,13S,14S,17S)-7-(4-(benzyloxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one(CAS DataBase Reference)
• NIST Chemistry Reference: (7S,8R,9S,13S,14S,17S)-7-(4-(benzyloxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one(1594940-99-4)
• EPA Substance Registry System: (7S,8R,9S,13S,14S,17S)-7-(4-(benzyloxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one(1594940-99-4)

Safety Data

• Hazardous Substances Data: 1594940-99-4(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 4541-14-4 4-benzyloxy-butan-1-ol 
• 486999-10-4 (8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one 
• 50873-94-4 (4-iodobutoxymethyl)benzene 
• 60789-54-0 4-bromobutyl benzyl ether 

Downstream Products

• 1594941-01-1 (7S,8R,9S,13S,14S,17S)-7-(4-(benzyloxy)butyl)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one 
• 1594941-04-4 (7R,8R,9S,13S,14S,17S)-7-(4-(benzyloxy)butyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol 
• 1594941-05-5 (7R,8R,9S,13S,14S,17S)-7-(4-(benzyloxy)butyl)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene 
• 1594941-09-9 4-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butyl 4-methylbenzenesulfonate 
• 1618678-50-4 (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butyl)-2-oxopiperazin-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1618678-51-5 (2S,4R)-1-((S)-2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 

Relevant articles and documents

Optimization of the alkyl side chain length of fluorine-18-labeled 7α-alkyl-fluoroestradiol

Introduction: Several lines of evidence suggest that 7α-substituted estradiol derivatives bind to the estrogen receptor (ER). In line with this hypothesis, we designed and synthesized 18F-labeled 7α-fluoroalkylestradiol (Cn-7α-[18F]FES) derivatives as molecular probes for visualizing ERs. Previously, we successfully synthesized 7α-(3-[18F]fluoropropyl)estradiol (C3-7α-[18F]FES) and showed promising results for quantification of ER density in vivo, although extensive metabolism was observed in rodents. Therefore, optimization of the alkyl side chain length is needed to obtain suitable radioligands based on Cn-7α-substituted estradiol pharmacophores. Methods: We synthesized fluoromethyl (23; C1-7α-[18F]FES) to fluorohexyl (26; C6-7α-[18F]FES) derivatives, except fluoropropyl (C3-7α-[18F]FES) and fluoropentyl derivatives (C5-7α-[18F]FES), which have been previously synthesized. In vitro binding to the α-subtype (ERα) isoform of ERs and in vivo biodistribution studies in mature female mice were carried out. Results: The in vitro IC50 value of Cn-7α-FES tended to gradually decrease depending on the alkyl side chain length. C1-7α-[18F]FES (23) showed the highest uptake in ER-rich tissues such as the uterus. Uterus uptake also gradually decreased depending on the alkyl side chain length. As a result, in vivo uterus uptake reflected the in vitro ERα affinity of each compound. Bone uptake, which indicates de-fluorination, was marked in 7α-(2-[18F]fluoroethyl)estradiol (C2-7α-[18F]FES) (24) and 7α-(4-[18F]fluorobutyl)estradiol (C4-7α-[18F]FES) (25) derivatives. However, C1-7α-[18F]FES (23) and C6-7α-[18F]FES (26) showed limited uptake in bone. As a result, in vivo bone uptake (de-fluorination) showed a bell-shaped pattern, depending on the alkyl side chain length. C1-7α-[18F]FES (23) showed the same levels of uptake in uterus and bone compared with those of 16α-[18F]fluoro-17β-estradiol. Conclusions: The optimal alkyl side chain length of 18F-labeled 7α-fluoroalkylestradiol was the shortest: C1-7α-[18F]FES. Our results indicate that shorter chain lengths within the 4-? ligand binding cavities of ERα are suitable for 7α-fluoroalkylestradiol derivatives.

PROTEOLYSIS TARGETING CHIMERAS (PROTACS) DIRECTED TO THE MODULATION OF THE ESTROGEN RECEPTOR

A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor